Vanda Pharmaceuticals (VNDA) CEO Says Company May Be Acquisition Target By Big Pharma

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) made positive comments on its Phase III trial of Iloperidone antipsychotic drug on CNBC. The CEO also said that other pharmaceutical companies have expressed interest in acquiring VNDA because of its strong pipeline.

NOTE: VNDA is up 60% in pre-open action today on the Phase III news